Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.
Boehringer Ingelheim Applauds the Governor's Prevention Partnership for Protecting Connecticut Youth from Drugs and Alcohol for 35 Years
Recently, our colleagues joined Governor Ned Lamont, and his Connecticut's Governor's Prevention Partnership organization to celebrate its 35th anniversary and reaffirm our collective commitment to keeping Connecticut youth safe and substance-free.
Boehringer Ingelheim collaborates with the Broad Institute
Boehringer Ingelheim and researchers at the Broad Institute of MIT and Harvard are collaborating to tackle the unmet needs of people living with mental health conditions.
Click here to read a few examples of the sustainability practices we’ve put in place at our U.S. HQ, to protect the planet for a more sustainable tomorrow.
FDA approves treatment option for T2D in children 10 and older
FDA has approved Jardiance® (empagliflozin) tablets to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes. See Safety, PI & Med Guide.